c-CBL Mutations Guide c-Met Inhibitor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for non-small cell lung cancer (NSCLC) have limited effectiveness, with overall survival rates remaining low despite advancements in molecularly targeted therapies, and there is a need for novel targeted therapies, particularly for African American patients and those with specific genetic mutations in the c-CBL gene.
Innovation Solution
Identifying subjects susceptible to treatment with c-Met inhibitors by determining the presence of specific mutations in the c-CBL gene, such as S80N, H94Y, Q249E, or L620F, which affect the efficacy of c-Met inhibitors, and using these mutations to tailor treatment approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current molecularly targeted therapies are used for NSCLC, then treatment options are expanded, but overall survival rates remain low
Solution Approach 1:
The patent applies local quality by identifying specific c-CBL mutation types (such as S80N, H94Y, Q249E, L620F) that have distinct functional consequences on c-Met inhibitor responsiveness. Rather than treating all NSCLC patients uniformly, the invention tailors treatment selection to the specific mutation subtype present in each patient's tumor, thereby improving survival outcomes through precision medicine approaches.
Solution Approach 2:
The patent utilizes parameter changes by analyzing specific amino acid substitutions in the c-CBL gene that alter protein function and drug response. By identifying mutations at specific positions (S80, H94, Q249, L620) and their impact on c-Met inhibitor efficacy, the invention transforms the approach from broad therapeutic categories to mutation-specific treatment parameters, enabling better prediction of treatment outcomes.
2Reliability
If personalized treatment strategies based on c-CBL mutations are implemented, then treatment responsiveness is enhanced, but diagnostic complexity increases
Solution Approach 1:
The patent extracts and focuses on specific, high-impact c-CBL mutation sites (S80N, H94Y, Q249E, L620F) that are most strongly associated with c-Met inhibitor responsiveness. By concentrating diagnostic efforts on these key mutation hotspots rather than analyzing the entire c-CBL gene sequence, the invention reduces diagnostic complexity while maintaining high predictive accuracy for treatment response.
Solution Approach 2:
The patent performs preliminary identification of c-CBL mutation status before treatment selection, allowing clinicians to predict responsiveness to c-Met inhibitors in advance. This upfront genetic characterization enables informed treatment decisions before initiating therapy, avoiding the need for complex real-time monitoring during treatment and simplifying the overall diagnostic workflow.
Data Source
AI summary
The present invention relates generally to the fields of molecular biology and growth factor regulation. The invention concerns methods and compositions useful for diagnosing and treating human lung cancer associated with mutated c-CBL.